Zelira Therapeutics (ZLDAF)
OTHER OTC:ZLDAF
ZLDAF Stock Chart & Stats
$0.21
-$0.03(-7.39%)
At close: 4:00 PM EST
$0.21
-$0.03(-7.39%)
Day’s Range― - ―
52-Week Range$0.20 - $0.48
Previous CloseN/A
Volume342.00
Average Volume (3M)189.00
Market Cap
$4.17M
Enterprise Value$8.08M
Total Cash (Recent Filing)$5.66K
Total Debt (Recent Filing)$2.14M
Price to Earnings (P/E)―
Beta0.65
Next Earnings
Sep 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.31
Shares Outstanding11,897,155
10 Day Avg. Volume15
30 Day Avg. Volume189
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)-1.13
Price to Sales (P/S)7702.11
P/FCF Ratio-1.03
Enterprise Value/Market Cap1.94
Enterprise Value/Revenue12.32K
Enterprise Value/Gross Profit-10.07
Enterprise Value/Ebitda-1.94
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary Cannabinoid PipelineZelira’s emphasis on proprietary cannabinoid medicines and consumer formulations indicates durable IP and product differentiation. Proprietary formulations can underpin regulatory approvals, licensing deals and margin expansion if clinical or commercial validation is achieved, supporting long-term value capture.
Diversified Monetization StrategyThe company targets multiple revenue pathways—direct product sales plus licensing/co-development—providing durable optionality. Licensing and B2B deals can create scalable, non-dilutive revenue streams and reduce reliance on single-channel sales, improving resilience across biotech cycles.
Lean Operating BaseA very small headcount implies a low fixed-cost structure and operational flexibility. In a capital-constrained biotech context, low payroll and overhead can extend runway, allow selective funding of R&D or commercialization, and reduce the urgency of dilutive financing in the medium term.
Bears Say
Severe Revenue DeclineA near-total collapse in revenue (~-98% YoY) indicates loss of commercial traction and persistent demand issues. Such extreme decline undermines the company’s ability to fund R&D, satisfy partners or scale distribution; recovery typically requires major new contracts, products, or capital injections.
Negative Stockholders' EquityNegative equity signals structural balance-sheet weakness that limits borrowing and credit access. It increases reliance on dilutive financing or asset sales, complicates partnership negotiations, and materially reduces financial flexibility needed to support long-term development and commercialization plans.
Negative Operating And Free Cash FlowsPersistent negative operating and free cash flows reflect ongoing cash burn and inability to self-fund operations. Even with slight FCF improvement, continued negative cash generation forces external financing or restructuring, constraining durable investment in trials, commercialization or scaling.
Zelira Therapeutics News
ZLDAF FAQ
What was Zelira Therapeutics’s price range in the past 12 months?
Zelira Therapeutics lowest stock price was $0.20 and its highest was $0.48 in the past 12 months.
What is Zelira Therapeutics’s market cap?
Zelira Therapeutics’s market cap is $4.17M.
When is Zelira Therapeutics’s upcoming earnings report date?
Zelira Therapeutics’s upcoming earnings report date is Sep 02, 2026 which is in 75 days.
How were Zelira Therapeutics’s earnings last quarter?
Currently, no data Available
Is Zelira Therapeutics overvalued?
According to Wall Street analysts Zelira Therapeutics’s price is currently Overvalued.
Does Zelira Therapeutics pay dividends?
Zelira Therapeutics does not currently pay dividends.
What is Zelira Therapeutics’s EPS estimate?
Zelira Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Zelira Therapeutics have?
Zelira Therapeutics has 11,897,155 shares outstanding.
What happened to Zelira Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Zelira Therapeutics?
Currently, no hedge funds are holding shares in ZLDAF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Zelira Therapeutics Stock Smart Score
Company Description
Zelira Therapeutics
Zelira Therapeutics Limited (ZLD.AX) is an Australian biopharmaceutical firm dedicated to the research, development, and commercialization of cannabinoid-derived medicines for a variety of medical conditions. Its product portfolio includes HOPE™ brand formulations, which are available in Pennsylvania and Louisiana, as well as Zenivol™, a cannabinoid-based medication designed to treat chronic insomnia. In addition to its prescription offerings, the company provides several over-the-counter (OTC) products. These include SprinJene™ for oral hygiene and RAF FIVE™ for dermatological applications. Zelira also markets ITURA™, an advanced topical relief cream formulated to target multiple symptoms such as numbness, tingling, muscle cramps, insensitivity, and pain associated with Peripheral Artery Disease and diabetes. Zelira maintains key strategic partnerships with academic and medical institutions, including Curtin University, the Telethon Kids Institute, the University of Western Australia, St. Vincent's Hospital, and the Children's Hospital of Philadelphia. Originally incorporated in 2003 as Zelda Therapeutics Limited, the company rebranded to Zelira Therapeutics Limited in December 2019. Its corporate headquarters are located in Perth, Australia.
Technical Analysis
Actinogen Medical
―
Tryptamine Therapeutics
―
Paradigm Biopharmaceuticals
―
Island Pharmaceuticals Ltd
―
Botanix Pharmaceuticals Limited
―